7 known cases. View patent page →
Hatch-Waxman ANDA patent infringement action in the District of New Jersey. The multi-patent Xyrem complaint included US 7,668,730 and also asserted the '059, '988, '182, and '963 patents. The case was resolved short of trial and closed.
Inter partes review of U.S. 8,589,182 B1. The PTAB held all challenged claims unpatentable as obvious over FDA Xyrem advisory-committee materials; rehearing was denied and the decision was affirmed by the Federal Circuit.
Federal Circuit appeal from the PTAB IPR decision on U.S. 8,589,182. The court affirmed, holding the FDA Advisory Committee materials were a publicly accessible printed publication and proper prior art; the decision disposed of the family patents together.
Inter partes review of U.S. 8,589,182. Wockhardt Bio AG challenged the patent, but the proceeding was terminated on July 27, 2016 after the parties settled.
Consolidated MDL antitrust litigation concerning Xyrem (sodium oxybate). U.S. 8,589,182 is listed among the patents cited/at issue. Class certification and summary-judgment motions have been decided; trial set for May 19, 2025.
Antitrust action filed June 18, 2020, cause 15:15 Antitrust, assigned to Judge Richard G. Seeborg. U.S. 8,589,182 is listed among the patents cited/at issue.
Jazz Pharmaceuticals sued Ranbaxy Laboratories and Ranbaxy Inc. in a Hatch-Waxman ANDA patent infringement action over generic sodium oxybate referencing Xyrem. The complaint asserted multiple patents including U.S. Patent No. 8,461,203. The case was consolidated for all purposes into Jazz Pharmaceuticals, Inc. v. Amneal Pharmaceuticals, LLC, No. 13-391-ES-JAD, and administratively terminated.